Literature DB >> 24658893

Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations.

D Amadori, P Serra, S Bravaccini, A Farolfi, M Puccetti, E Carretta, L Medri, O Nanni, M M Tumedei, J Kahima, N Masalu.   

Abstract

Information on hormone receptor and human epidermal growth factor receptor-2 (HER2) expression in breast cancer is acknowledged as mandatory for prognostic stratification and treatment planning. Data on the biological features of African breast cancers are poor. We decided to compare histopathological and biomolecular characteristics (estrogen and progesterone receptorER, PgR, and HER2) of Tanzanian and Italian breast cancers. Differences in proliferating index and androgen receptor (AR) expression in triple-negative patients from the two case series were also assessed. Of the 103 consecutive patients seen at the Bugando Medical Center (Mwanza, Tanzania) from 2003 to 2010, who underwent biopsy or surgical resection of primary breast cancer, 69 patients had tissue samples that were evaluable for estrogen receptor (ER), progesterone receptor (PgR), and HER2. Histopathological assessment and biomolecular determinations were performed at the Cancer Institute of Romagna (IRST IRCCS, Meldola, Italy). Caucasian breast cancers were randomly extracted from an electronic database and matched (1:2 ratio) for year of diagnosis and age at diagnosis. Median age of both populations was 51 years (range 27–84). With respect to Caucasian tumors, Tanzanian breast cancers at diagnosis more frequently showed high histological grade (mainly grade 3) (P = 0.03), advanced clinical stage (III or IV) (P\0.001), ER negativity (52.2 %, P\0.001) and high proliferation (P = 0.0002). Triple-negative tumors were over-represented in Tanzanian women. AR was positive in 38.5 and 38 %of triple-negative Tanzanian and Italian breast cancers, respectively. Our results show that histopathological and biomolecular characteristics in Tanzanian and Italian breast cancers differ substantially. The high frequency of poorly differentiated, ER-negative, highly proliferating tumors, together with advanced stage at presentation, could be considered as the main prognostic factors linked to the high mortality rates for breast cancer in the African population.

Entities:  

Mesh:

Year:  2014        PMID: 24658893     DOI: 10.1007/s10549-014-2903-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.

Authors:  Sara Ravaioli; Maria Maddalena Tumedei; Flavia Foca; Roberta Maltoni; Andrea Rocca; Ilaria Massa; Elisabetta Pietri; Sara Bravaccini
Journal:  Int J Exp Pathol       Date:  2017-11-28       Impact factor: 1.925

2.  Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway.

Authors:  Dino Amadori; Patrizia Serra; Nestory Masalu; Akwilina Pangan; Emanuela Scarpi; Aloyce Maria Bugingo; Deogratias Katabalo; Toni Ibrahim; Alberto Bongiovanni; Giacomo Miserocchi; Chiara Spadazzi; Chiara Liverani; Valentina Turri; Rosanna Tedaldi; Laura Mercatali
Journal:  Oncotarget       Date:  2017-02-21

3.  Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?

Authors:  Sara Bravaccini; Sara Ravaioli; Dino Amadori; Emanuela Scarpi; Maurizio Puccetti; Andrea Rocca; Maria Maddalena Tumedei; Nestory Masalu; Jackson Kahima; Akwilina Pangan; Lucas Faustine; Alberto Farolfi; Roberta Maltoni; Massimiliano Bonafè; Patrizia Serra; Giuseppe Bronte
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-29       Impact factor: 5.555

4.  Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes.

Authors:  Alex Mremi; Gloria Broadwater; Kahima Jackson; Patrick Amsi; Cosmas Mbulwa; Terry Hyslop; Cecilia Ong; Allison Hall
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

5.  Evaluating Estrogen Receptor Immunohistochemistry on Cell Blocks From Breast Cancer Patients in a Low-Resource Setting.

Authors:  Asteria H Kimambo; Edda A Vuhahula; Amos R Mwakigonja; Britt-Marie Ljung; Li Zhang; Katherine Van Loon; Dianna L Ng
Journal:  Arch Pathol Lab Med       Date:  2021-07-01       Impact factor: 5.686

6.  Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.

Authors:  Ana Cláudia de Macêdo Andrade; Carlos Alberis Ferreira Júnior; Beatriz Dantas Guimarães; Ana Waleska Pessoa Barros; Gibran Sarmento de Almeida; Mathias Weller
Journal:  BMC Womens Health       Date:  2014-09-12       Impact factor: 2.809

7.  Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.

Authors:  Hawa Nalwoga; Lavina Ahmed; Jarle B Arnes; Henry Wabinga; Lars A Akslen
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

8.  Understanding women's perspectives on breast cancer is essential for cancer control: knowledge, risk awareness, and care-seeking in Mwanza, Tanzania.

Authors:  Christina A Chao; Liuye Huang; Kala Visvanathan; Kisa Mwakatobe; Nestory Masalu; Anne F Rositch
Journal:  BMC Public Health       Date:  2020-06-15       Impact factor: 3.295

9.  Comparison of Receptor-Defined Breast Cancer Subtypes Between German and Sudanese Women: A Facility-Based Cohort Study.

Authors:  Asmerom Tesfamariam Sengal; Nada Suliman Haj Mukhtar; Martina Vetter; Ahmed Mohammed Elhaj; Shahinaz Bedri; Steffen Hauptmann; Christoph Thomssen; Ahmed Abdalla Mohamedani; Claudia Wickenhauser; Eva Johanna Kantelhardt
Journal:  J Glob Oncol       Date:  2017-08-04

10.  Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold.

Authors:  Roberta Maltoni; Michela Palleschi; Sara Ravaioli; Maria Maddalena Tumedei; Mattia Altini; Sara Bravaccini
Journal:  Diagn Pathol       Date:  2020-09-11       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.